Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHI NASDAQ:PLRZ NASDAQ:RNAZ NASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$0.72$0.72$0.38▼$2.03$29.10M1.14170,509 shs117,067 shsPLRZPolyrizon$13.80$13.90$2.88▼$18.20$28.76M-1.5937,749 shs117,165 shsRNAZTransCode Therapeutics$8.61$6.26$3.82▼$20.99$8.18M1.2330,295 shs51,137 shsTXMDTherapeuticsMD$2.11$2.06$0.99▼$2.95$24.42M0.5964,147 shs13,601 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma0.00%+16.79%-18.50%+13.97%-58.85%PLRZPolyrizon0.00%+20.21%+2.53%+14.24%+219.44%RNAZTransCode Therapeutics0.00%+73.24%+70.83%-1.49%+3.86%TXMDTherapeuticsMD0.00%0.00%+7.11%+5.50%+85.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$0.72$0.72$0.38▼$2.03$29.10M1.14170,509 shs117,067 shsPLRZPolyrizon$13.80$13.90$2.88▼$18.20$28.76M-1.5937,749 shs117,165 shsRNAZTransCode Therapeutics$8.61$6.26$3.82▼$20.99$8.18M1.2330,295 shs51,137 shsTXMDTherapeuticsMD$2.11$2.06$0.99▼$2.95$24.42M0.5964,147 shs13,601 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma0.00%+16.79%-18.50%+13.97%-58.85%PLRZPolyrizon0.00%+20.21%+2.53%+14.24%+219.44%RNAZTransCode Therapeutics0.00%+73.24%+70.83%-1.49%+3.86%TXMDTherapeuticsMD0.00%0.00%+7.11%+5.50%+85.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/APLRZPolyrizon 1.00SellN/AN/ARNAZTransCode Therapeutics 1.00SellN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest RNAZ, CPHI, PLRZ, and TXMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/6/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$3.99M7.29N/AN/A$0.70 per share1.03PLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/ATXMDTherapeuticsMD$3.02M8.08$0.05 per share45.23$2.32 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08M-$0.55N/AN/AN/A-85.56%-63.93%-31.42%N/APLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ARNAZTransCode Therapeutics-$34.66M-$50.33N/AN/AN/AN/A-875.35%-50.36%8/18/2026 (Estimated)TXMDTherapeuticsMD-$570K$0.0635.17N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)Latest RNAZ, CPHI, PLRZ, and TXMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RNAZTransCode TherapeuticsN/A-$21.28N/A-$21.28N/AN/A5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26PLRZPolyrizonN/A29.0329.03RNAZTransCode TherapeuticsN/A3.113.11TXMDTherapeuticsMDN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/APLRZPolyrizonN/ARNAZTransCode TherapeuticsN/ATXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma6.40%PLRZPolyrizonN/ARNAZTransCode Therapeutics0.10%TXMDTherapeuticsMD1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionablePLRZPolyrizonN/A2.08 millionN/AN/ARNAZTransCode Therapeutics9950,000949,000Not OptionableTXMDTherapeuticsMD42011.57 million11.38 millionOptionableRNAZ, CPHI, PLRZ, and TXMD HeadlinesRecent News About These CompaniesTherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comTherapeuticsMD Explains Brief Delay In Annual FilingApril 1, 2026 | tipranks.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | finance.yahoo.comTherapeuticsMD Announces Full Year 2025 Financial ResultsMarch 30, 2026 | businesswire.comTherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 SharesDecember 30, 2025 | insidertrades.comTherapeuticsMD approves key proposals at annual meetingDecember 16, 2025 | msn.comTherapeuticsMD: Q3 Earnings SnapshotNovember 13, 2025 | timesunion.comTTherapeuticsMD Reports Q3 2025 Financial ResultsNovember 13, 2025 | msn.comTherapeuticsMD Announces Third Quarter 2025 Financial ResultsNovember 12, 2025 | businesswire.comTherapeuticsMD Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comTherapeuticsMD: Q2 Earnings SnapshotAugust 12, 2025 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAZ, CPHI, PLRZ, and TXMD Company DescriptionsChina Pharma NYSE:CPHI$0.72 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.72 +0.00 (+0.14%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Polyrizon NASDAQ:PLRZ$13.80 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$13.00 -0.80 (-5.79%) As of 07/2/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.TransCode Therapeutics NASDAQ:RNAZ$8.61 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$8.76 +0.15 (+1.74%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.TherapeuticsMD NASDAQ:TXMD$2.11 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
